On Tuesday, January 8th, 2019, Orthopedics This Week reports about a multicenter study from Northwestern University, The University of California-Davis, and the OLVG Hospital in Amsterdam, that has looked into costs associated with employing the Barricaid annular closure device for patients who are at high risk for recurrent herniation after a discectomy. Their work, “Cost-effectiveness of a bone-anchored annular […]
Read moreIn the News
Barricaid superiority data presented at 25th Brussels international spine symposium
NewsThe Brussels International Spine Symposium (BISS) is globally recognized as one of the world leading, state-of-art annual meetings in Spine. Under the auspice of Drs. Marek Szpalski and Robert Gunzburg, the 25th anniversary meeting took place on 16-17 November 2018 reviewing the topic of Disc Herniation – Back to Basics: Controversies in diagnosis, management and costs. One […]
Read moreBest Paper Award SSA 2018 presented to Dr. Mark Arts
NewsDr. Mark Arts, a Dutch neurosurgeon from The Hague, delivered two podium presentations at the 2018 Spine Society of Australia 29th Annual Scientific Meeting, 27-29 April in Adelaide. One of his presented abstracts was elected as Best Paper of the 2018 Annual Scientific Meeting. Both talks were delivered in the Free Paper Session that focused on […]
Read more
Intrinsic Therapeutics announces the completion of a $49m financing
Press ReleaseFUNDING SUPPORTS FDA APPROVAL PROCESS AND GLOBAL MARKET ACCESS Boston, MA- May 10, 2017 -8:00am EST – Intrinsic Therapeutics, Inc. a medical device company that has developed a product to improve outcomes in lumbar discectomy patients, announced today that it recently closed a $49 million round of financing. The financing included a $28 million equity round […]
Read moreIntrinsic Therapeutics announces the filing of PMA application for its Barricaid Annular Closure device for lumbar discectomy patients
Press ReleaseBOSTON, Dec. 21, 2016 Intrinsic Therapeutics, Inc. announced today that the filing of its Pre-Market Approval (PMA) application with the Food & Drug Administration (FDA) for the Barricaid® Annular Closure device is complete. Barricaid has been shown to improve the outcomes of patients undergoing discectomy for herniated lumbar discs to relieve sciatica pain. “Approximately 1 million […]
Read moreIntrinsic Therapeutics announces the enrollment of the 400th patient in landmark Barricaid randomized trial
Press ReleaseIntrinsic Therapeutics today announced the enrollment of the 400th patient in a level 1, prospective, randomized, multi-center clinical trial evaluating the effectiveness of its Barricaid Prosthesis in improving outcomes for lumbar discectomy patients suffering from sciatica. The surgery was performed by Dr. Frederic Martens in Aalst, Belgium. The study is being conducted in Germany, Switzerland, Austria, and The Benelux with the goal […]
Read moreIntrinsic Therapeutics announces enrollment of 300th patient in Barricaid randomized trial
Press ReleaseIntrinsic Therapeutics, a Medical Device Spine company, today announced a key milestone in a clinical study of its Barricaid® Prosthesis: 300 patients are now enrolled in a prospective, randomized, multi-center trial to definitively establish the safety and effectiveness of the implant. This Level 1 controlled study is being conducted across five countries in Europe and is expected […]
Read moreIntrinsic Therapeutics, Inc. names Cary P. Hagan as President and CEO
Press ReleaseIntrinsic Therapeutics, a medical device company focused on developing therapies to address the spine market’s many unmet needs, today announced that Cary Hagan has been appointed President and Chief Executive Officer. Mr. Hagan brings over 20 years of experience in the orthopedic implant field with significant expertise in product development, commercialization and global marketing strategy. Greg Lambrecht, Founder […]
Read moreIntrinsic enrolls first patient in Barricaid trial
Press ReleaseIntrinsic Therapeutics, Inc., a developer of novel lumbar spine anulus closure devices, announced today that it has enrolled the first patient, December 17, 2010, in a Randomized Clinical Trial of its Barricaid® device. Barricaid is designed to prevent reherniations following lumbar discectomy, while allowing the surgeon to retain as much of the native nucleus as possible […]
Read more